No black box warning on record for Nexobrid

As of the latest FDA labeling reviewed, Nexobrid (ANACAULASE-BCDB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Nexobrid medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions : Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NEXOBRID (if applicable) and initiate appropriate therapy ( 5.1 ). Coagulopathy: Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution i

No black box warning on record for Nexobrid

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions : Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NEXOBRID (if applicable) and initiate appropriate therapy ( 5.1 ). Coagulopathy: Avoid use of NEXOBRID in patients with uncontrolled disorders of coagulation. Use with caution i

Nexobrid Black Box Warning

No black box warning on record for Nexobrid

Other warnings & precautions

Nexobrid Black Box Warning

No black box warning on record for Nexobrid

Other warnings & precautions